Eric Ferrari

2.1k total citations · 1 hit paper
17 papers, 1.4k citations indexed

About

Eric Ferrari is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Eric Ferrari has authored 17 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hepatology, 10 papers in Infectious Diseases and 9 papers in Epidemiology. Recurrent topics in Eric Ferrari's work include Hepatitis C virus research (11 papers), Hepatitis B Virus Studies (8 papers) and HIV/AIDS drug development and treatment (7 papers). Eric Ferrari is often cited by papers focused on Hepatitis C virus research (11 papers), Hepatitis B Virus Studies (8 papers) and HIV/AIDS drug development and treatment (7 papers). Eric Ferrari collaborates with scholars based in United States, Slovakia and India. Eric Ferrari's co-authors include Zhi Hong, Charles A. Lesburg, Patricia C Weber, Michael Cable, Anthony Mannarino, Johnson Y. N. Lau, Jacquelyn Wright-Minogue, Weidong Zhong, Zhi Hong and Annette S. Uss and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Virology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Eric Ferrari

17 papers receiving 1.3k citations

Hit Papers

1999 2026 2008 2017 1999 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Ferrari United States 13 864 581 492 470 323 17 1.4k
Peter Friebe Germany 14 1.3k 1.5× 923 1.6× 364 0.7× 578 1.2× 345 1.1× 16 1.9k
Jacquelyn Wright-Minogue United States 13 549 0.6× 435 0.7× 294 0.6× 178 0.4× 174 0.5× 17 840
Shihyun You United States 14 485 0.6× 466 0.8× 434 0.9× 414 0.9× 155 0.5× 21 1.4k
Gennadiy Koev United States 19 703 0.8× 564 1.0× 429 0.9× 237 0.5× 117 0.4× 25 1.3k
Takashi Shimoike Japan 17 449 0.5× 362 0.6× 237 0.5× 391 0.8× 200 0.6× 24 1.1k
Lucyna Cova France 26 718 0.8× 1.1k 2.0× 511 1.0× 333 0.7× 87 0.3× 71 1.7k
B. Wolanski United States 15 304 0.4× 399 0.7× 402 0.8× 478 1.0× 95 0.3× 25 1.1k
Kyung-Soo Chang South Korea 12 532 0.6× 595 1.0× 105 0.2× 182 0.4× 57 0.2× 57 999
M. Homma Japan 23 119 0.1× 857 1.5× 404 0.8× 346 0.7× 98 0.3× 59 1.4k
Kevin Whitby United Kingdom 14 423 0.5× 529 0.9× 775 1.6× 348 0.7× 51 0.2× 20 1.7k

Countries citing papers authored by Eric Ferrari

Since Specialization
Citations

This map shows the geographic impact of Eric Ferrari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Ferrari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Ferrari more than expected).

Fields of papers citing papers by Eric Ferrari

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Ferrari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Ferrari. The network helps show where Eric Ferrari may publish in the future.

Co-authorship network of co-authors of Eric Ferrari

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Ferrari. A scholar is included among the top collaborators of Eric Ferrari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Ferrari. Eric Ferrari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Asante‐Appiah, Ernest, Rong Liu, Stephanie Curry, et al.. (2018). In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A. Antimicrobial Agents and Chemotherapy. 62(11). 4 indexed citations
2.
Bennett, Frank, Alexei V. Buevich, Hsueh‐Cheng Huang, et al.. (2017). Concise syntheses and HCV NS5B polymerase inhibition of (2′R)-3 and (2′S)-2′-ethynyluridine-10 and related nucleosides. Bioorganic & Medicinal Chemistry Letters. 27(23). 5349–5352. 2 indexed citations
3.
Ferrari, Eric & Hsueh‐Cheng Huang. (2013). A Novel Hepatitis C Virus NS5B Polymerase Assay of De Novo Initiated RNA Synthesis Directed from a Heteropolymeric RNA Template. Methods in molecular biology. 1030. 81–92. 3 indexed citations
4.
Cheng, Cliff C., Gerald W. Shipps, Zhiwei Yang, et al.. (2010). Inhibitors of hepatitis C virus polymerase: Synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides. Bioorganic & Medicinal Chemistry Letters. 20(7). 2119–2124. 20 indexed citations
5.
Cheng, Cliff C., Xiaohua Huang, Gerald W. Shipps, et al.. (2010). Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase. ACS Medicinal Chemistry Letters. 1(9). 466–471. 16 indexed citations
6.
Ferrari, Eric, Zhiqing He, Robert E. Palermo, & Hsiao‐Ching Huang. (2008). Hepatitis C Virus NS5B Polymerase Exhibits Distinct Nucleotide Requirements for Initiation and Elongation. Journal of Biological Chemistry. 283(49). 33893–33901. 25 indexed citations
7.
Zhong, Weidong, Annette S. Uss, Eric Ferrari, Johnson Y. N. Lau, & Zhi Hong. (2000). De Novo Initiation of RNA Synthesis by Hepatitis C Virus Nonstructural Protein 5B Polymerase. Journal of Virology. 74(4). 2017–2022. 162 indexed citations
8.
Zhong, Weidong, Eric Ferrari, Charles A. Lesburg, et al.. (2000). Template/Primer Requirements and Single Nucleotide Incorporation by Hepatitis C Virus Nonstructural Protein 5B Polymerase. Journal of Virology. 74(19). 9134–9143. 97 indexed citations
9.
Nielsen, Loretta L., Bin Shi, Gerald Hajian, et al.. (1999). Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models.. PubMed. 59(23). 5896–901. 26 indexed citations
10.
Weber, Patricia C, Charles A. Lesburg, Michael Cable, et al.. (1999). Nature Structural Biology. 6(10). 937–943. 597 indexed citations breakdown →
11.
Ferrari, Eric, Jacquelyn Wright-Minogue, Jane Fang, et al.. (1999). Characterization of Soluble Hepatitis C Virus RNA-Dependent RNA Polymerase Expressed in Escherichia coli. Journal of Virology. 73(2). 1649–1654. 210 indexed citations
12.
Lai, Vicky C. H., C. Cheng Kao, Eric Ferrari, et al.. (1999). Mutational Analysis of Bovine Viral Diarrhea Virus RNA-Dependent RNA Polymerase. Journal of Virology. 73(12). 10129–10136. 94 indexed citations
13.
Buontempo, Peter, Stuart Cox, Jacquelyn Wright-Minogue, et al.. (1997). SCH 48973: a potent, broad-spectrum, antienterovirus compound. Antimicrobial Agents and Chemotherapy. 41(6). 1220–1225. 45 indexed citations
14.
Chase, Robert A., Eric Ferrari, Angela Skelton, et al.. (1997). SCH 43478 and analogs: in vitro activity and in vivo efficacy of novel agents for herpesvirus type 2. Antiviral Research. 35(3). 139–146. 27 indexed citations
15.
Schwartz, Jerome, et al.. (1997). Production of recombinant herpes simplex virus protease in 10-L stirred vessels using a baculovirus-insect cell expression system. Journal of Industrial Microbiology & Biotechnology. 19(2). 87–91. 3 indexed citations
16.
Cox, Stuart, Peter Buontempo, Jacquelyn Wright-Minogue, et al.. (1996). Antipicornavirus activity of SCH 47802 and analogs: in vitro and in vivo studies. Antiviral Research. 32(2). 71–79. 22 indexed citations
17.
Hong, Zhi, Eric Ferrari, Jacquelyn Wright-Minogue, et al.. (1996). Enzymatic characterization of hepatitis C virus NS3/4A complexes expressed in mammalian cells by using the herpes simplex virus amplicon system. Journal of Virology. 70(7). 4261–4268. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026